This is a proposal to investigate the role of microRNAs in autoimmune diseases. Collectively, 5-10% of the western population is affected by some of the more than 80 autoimmune diseases that arise when the immune system attacks its own body. Current treatment options have limited efficacy, are expensive and have severe side effects such as increased risk for infections and cancer. In the long-term we aim to exploit microRNAs to control the immune system gone awry in patients with autoimmune diseases in order to restore immune homeostasis. Regulatory T cells (Treg) are cells of the immune system specialized to suppress immune responses. Due to their proven ability to prevent and even cure preclinical animal models of autoimmune diseases such as Type 1 diabetes and multiple sclerosis and their important role in preventing rejection of transplanted organs, Treg have entered clinical trials. In contrast, T follicular helper (TFH) cells provide classic "help" to B clls supporting the B cells'function to produce high-affinity antibodies. Both, dysregulation of Treg o TFH promote autoimmunity. microRNAs are regulators of gene expression only discovered relatively recently. Therefore our understanding of microRNA function in the immune system is very limited. Using in vivo gene ablation we showed the importance of the miRNA cluster miR-17-92 for Treg and TFH function. It is intriguing that miR-17- 92 sustains both, promoters and inhibitors of immune responses, respectively. [An important new finding is that miR-17-92 represses subset-inappropriate gene expression during TFH differentiation. Accordingly, we have refined the experiments to delineate in detail how miR-17-92 regulates T cell differentiation with a particular emphasis on the cell fate decision to differentiate into TFH rather than alternative T cell subsets. We propose that in the absence of miR-17-92 the cells respond to environmental cues they are not supposed to receive. We will characterize in depth the consequences of these inappropriate signals during TFH differentiation which will teach us what the normal function of miR-17-92 is. We will further assess if the same pathways are regulated by miR-17-92 in the functionally opposing Treg cells.] We will use cell culture assays and [mouse models used to generate TFH cells after infection and a model of acute autoimmune disease: experimental autoimmune encephalitis.] We are using mice that lack the miR-17-92 cluster in all T cells including TFH or only in Treg. The revised specific aims of this proposal ar: 1) [Exploring the role of miR-17-92 in sensing cytokines as a basis for cell fate determination] 2) Determine the molecular [basis] of miR-17-92 function in TFH and Treg.

Public Health Relevance

Autoimmune diseases affect 5-10% of the western population and cause tremendous suffering and billions of annual health care costs. We will investigate how genes called microRNAs prevent the development of these debilitating diseases. The proposed experiments [are designed to improve the basic understanding how one particular microRNA locus called the miR-17-92 cluster regulates T cell subsets implicated in the promotion and prevention of autoimmune diseases. We anticipate that the results could] lay the basis for rationale design of a novel class of therapeutics targeting the miR-17-92 cluster.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
1R01AI106923-01A1
Application #
8697657
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Rothermel, Annette L
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University Hospital Basel
Department
Type
DUNS #
City
Basel
State
Country
Switzerland
Zip Code